CONNECT

The CDMO that’s changing the game.

RESI-24-003d-3DKA__09-PAD_Persp02-Red_v4

Driving Innovative Biomanufacturing

The technology of biomanufacturing complex medicines, like cell and gene therapies, hasn’t kept pace with the wave of scientific discoveries fueling them. That’s why Resilience is bringing together brilliant minds in science and engineering with access to the most advanced technologies to build the CDMO pursuing a more resilient tomorrow, today.

Resilience Logomark

Manufacturing solutions custom-fit to your needs

We were founded with a straightforward yet bold purpose: to broaden access to complex medicines and to protect biopharmaceutical supply chains against disruption. At the heart of our approach is a network of high-tech, end-to-end drug substance and drug product manufacturing solutions that can help ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

RESI-24-003d-3DKA-07-SC-Pesrp01-FG-2

Sized right for every challenge

You don’t have to be a big company to be treated like one: If you’re part of a small or mid-sized biotech, you’ll welcome our hands-on support with the kind of capacity that can grow as your needs do.

What's new at Resilience

scroll
Filter
On Demand Webinar:  Fill/Finish Services - Outsourced Pharma Capacity Update
Cell Therapy Innovations: Reducing Costs to Improve Patient Access
Executive Interview: Advancing Therapies That Transform Lives
Resilience and JobsOhio Announce Continued Partnership and Expansion in Blue Ash
Fact Sheet: Kona Multiomics Characterization Assay Services
Presentation: Rapid Multi-Omics Cell Therapy Characterization and QC
Whitepaper: 3-Day Short Cycle CAR-T Manufacturing Process
Resilience is proud to support CARGO Therapeutics' novel allogeneic CAR-T cell therapy
Presentation: Expedited Cell Therapy QC: Sample in, to QC Report in 48 Hours 
Resilience Partners with Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
Resilience Announces Appointment of William S. Marth, RPh., MBA as Chief Executive Officer
On-Demand Webinar: Outsourced Pharma Capacity Update - Drug Substance
Key Steps in the Vaccine Scale-up Journey
Resilience Secures Funding to Expand Domestic Manufacturing for Critical Pharmaceutical Ingredients
Resilience Appoints Dr. Susan Billings, Chief Commercial Officer
Boston, MA: Process & Analytical Development and Manufacturing Facility
On-Demand Webinar: Outsourced Pharma Capacity Update - Fill/Finish
On-Demand Presentation: Improving cell line development in CHO with a focus on product manufacturability
Meet the Team: Viral Vector Development & Manufacturing
Alachua Campus Tour Video
Revised Annex 1 and the Focus on Microbial Control Strategies
Starburst Data Rebel Awards: Data Product of the Year
Building Velocity into Fill/Finish Timelines: Your Guide to Quality and Regulatory Success in the CDMO Space
On-Demand Webinar: Outsourced Pharma Capacity Update 2024 - Large Molecules
On-demand Webinar: Optimize research and delivery of complex medicines using data insights
Resilience Expands Clinical and Commercial Drug Product Manufacturing Capabilities and Capacities
Scale Your Vaccine Development with Path-to-PAD
How Resilience Is Bringing Forward Thinking to Disrupt the Biomanufacturing Landscape to Increase Access to Medicines
National Resilience and Taiwan Bio-Manufacturing Corporation Announce Groundbreaking Partnership in Biomanufacturing Innovation
Successful Development and Manufacturing of Vaccines Containing Aluminum Adjuvants
Developing New Medicines Through Artificial Intelligence
Resilience to Present at the 42nd Annual J.P. Morgan Healthcare Conference
The Stage-Gate Model: A Proven Approach to Streamline Biomanufacturing
Resilience builds lab supply chain tracking platform on AWS
On-demand Video: Efficiency Meets Economy: The Power of Single-Use Chromatography in mAb Purification
Resilience Announces Expansion in West Chester
How digital twins help improve biomanufacturing quality and security
On-demand Video: Idea to Clinic – Aim to Reduce your Manufacturing Timeline by ~30%
Resilience Appoints Bill Marth as President of Services
Accelerating Clinical Timelines of Induced Pluripotent Stem Cells (iPSCs) with Pluristyx
BridgeBio and Resilience Announce Strategic Multi-Year Partnership
The Challenges and Solutions for Viral Products
How Early-Phase Companies Can Future-Proof Their Cell Therapies
Resilience Announces Joint Venture with Lifera in Saudi Arabia
Opening of Resilience's West Coast Cell Therapy PAD Center
On-Demand Webinar: High-Throughput Process & Analytical Platforms to Accelerate Gene Therapy Scale-Up
Overcoming Obstacles in Gene Therapy Manufacturing
On-Demand Webinar: Future-Proof Your Aseptic Filling
Resilience Enters Into Strategic Collaboration with Labcorp to Accelerate Cell and Gene Therapies
Problem Solving for Aseptic Filling
On Demand Webinar: Outsourced Pharma Capacity Update-Large Molecules
Leveraging Partnerships to Achieve Cell Therapy Success
Master Cell Banks: Laying the Foundation to Final Product Success
Resilience Approved For $410M Financing From The Department Of Defense, In Partnership With The Development Finance Corporation, To Establish Resilient Biomanufacturing Capacity
Looking Ahead: What Does the Future Have in Store for Nucleic Acid-Based Therapies?
Resilience Signs Multi-Year Strategic Biomanufacturing Partnership With Leading Pharmaceutical Company
Alachua Biomanufacturing Expansion Video
Resilience Announces Equity Investment From Mubadala And Funding Of New Biopharma Manufacturing Facility In The United Arab Emirates
Resilience to Establish Biomanufacturing Partnership with AstraZeneca and Purchase Manufacturing Site
Cell Therapy – What Does It Take To Become a Mainstream Option
On Demand Drug Substance Manufacturing and Drug Product Fill/Finish Solutions Presentation
Resilience To Establish A Biomanufacturing Partnership With AstraZeneca And Purchase AstraZeneca’s Manufacturing Site In West Chester, Ohio
National Resilience Honored By Goldman Sachs For Entrepreneurship
On-Demand Webinar: Establishing a Stage-Gate Approach to Biomanufacturing
Resilience Becomes Biomanufacturing Resource Partner For California Institute For Regenerative Medicine
Resilience Announces Collaboration To Manufacture And Deliver Biotherapeutics For Rare And Complex Conditions
The Parker Institute For Cancer Immunotherapy And Resilience Announce Strategic Alliance To Develop Next-Generation Cancer Therapies
Resilience Announces $625 Million Series D Financing To Expand Network, Bring Innovative Technologies To Biomanufacturing
Resilience And MD Anderson Launch Joint Venture To Accelerate Development And Manufacturing Of Innovative Cell Therapies For Cancer
Resilience Establishes Multi-Product Development And Manufacturing Collaboration With Takeda’s Plasma-Derived Therapies Business Unit
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million From U.S. Department Of Defense For Botulinum Neurotoxin Treatment
Resilience Acquires SwiftScale Biologics, A Leader In Cell-Free Protein Synthesis Technology
Resilience And Harvard University Announce Five-Year R&D Alliance To Incubate New Technologies, Launch Companies To Advance The Manufacture Of Complex Medicines
Resilience Joins Forces With Children’s Hospital Of Philadelphia To Develop Next-Generation Biomanufacturing Technologies, Create Impactful Therapies
Resilience To Manufacture mRNA For Moderna’s COVID-19 Vaccine
Meet The 24 Biotech Startups That Top VCs Say Are Poised To Take Off In The next 12 Months
Bluebird Bio And Resilience Announce Strategic Alliance To Develop Next Generation Cell Therapies
Resilience Receives USD $164 Million Investment From The Government of Canada to Modernize and Expand Its Ontario Biomanufacturing Site, Improving Pandemic Preparedness
Resilience Continues Expansion With Acquisition Of Biologics Manufacturing Company Ology Bioservices
How An East Bay Site May Lead A Biotech Manufacturing Revolution
With Stars Aligned And Cash In Reserve, Bob Nelsen’s Resilience Plans A Makeover At 2 New Facility Additions To Its Drug Manufacturing Upstart
Resilience Expands North American Capacity With The Acquisition Of Two Premier Biologics Manufacturing Facilities
Fireside Chat With Rahul Signhvi, CEO Of Resilience
Resilience Bags Sanofi-Genzyme Plant In Boston
Sanofi Prepares To Transfer Allston Plant To A New Company, But Not Its City Tax Breaks
Raging At The Pandemic, A VC Raises $800M For A Company That Aims To Transform Biotech Manufacturing
Resilience Launches To Change The Future Of Medicine Through Manufacturing Innovation
Vaccine-Graphic

The benefits of working with Resilience

When you engage with Resilience as your CDMO biomanufacturing partner, you get the kind of thinking – backed by the kind of resources necessary – to future-proof the next stages of your discovery. We do that by delivering three crucial advantages to your team:

01.

Flexibility to accommodate your individual project needs, equipped with expertise and ample capacity to execute

02.

Access to best-in-class development platforms derived from breakthroughs across key modalities

03.

Delivering on the promise of cloud-based systems, advanced AI, and next-level visibility and data security

resi-mobile-vaccine-1
resilience-bg-hero-culture-05-2

Facilities

Resilience is North America based, with facilities across the continental US and Canada. Our regulatory expertise spans across global markets and serves our customers in EU, Asia, the Middle East, and North America.

Contact Us

chevrons-pattern-black-1